Effect of Lidocaine With Magnesium Sulfate on the Success of the Inferior Alveolar Nerve Block

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-09-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: stagepatientpatientscelltherapy
  Phrases that lowered it: healthyinjectionthe studyexaminationbody
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports marked serious: 54.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Blinding: single (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Sponsor's past trials: 61 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 8283 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Lidocaine/Dexamethasone on the Success of IANB NCT03531970 · started 2016 · scored riskier than 5% of active trials completed
• Effect of Addition of Mannitol to Bupivacaine on IANB Success and Post-endodontic Pain NCT03749408 · started 2012 · scored riskier than 6% of active trials completed
• Efficacy of Combining an Inferior Alveolar Nerve Block With a Buccal Infiltration NCT06276842 · started 2020 · scored riskier than 6% of active trials completed
• Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis NCT05840913 · started 2023 · scored riskier than 5% of active trials completed
• Effect of Preoperative Oral Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Block With Supplemental Buccal and Lingual Infiltrations Using Articaine in Mandibular Molar Teeth With Irreversible Pulpitis NCT05927922 · started 2023 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.